Literature DB >> 8001360

The case for confidence intervals in controlled clinical trials.

M Borenstein1.   

Abstract

A statistical wit once remarked that researchers often pose the wrong question and then proceed to answer that question incorrectly. The question that researchers intend to ask is whether or not a treatment effect is clinically significant. The question that is typically asked, however, is whether or not the treatment effect is statistically significant--a question that may be only marginally related to the issue of clinical impact. Similarly, the response, in the form of a p value, is typically assumed to reflect clinical significance but in fact reflects statistical significance. In an attempt to address this problem the medical literature over the past decade has been moving away from tests of significance and toward the use of confidence intervals. Concretely, study reports are moving away from "the difference was significant with a p value under 0.01" and toward "the one-year survival rate was increased by 20 percentage points with a 95% confidence interval of 15 to 24 percentage points." By focusing on what the effect is rather than on what the effect is not confidence intervals offer an appropriate framework for reporting the results of clinical trials. This paper offers a non-technical introduction to confidence intervals, shows how the confidence intervals framework offers advantages over hypothesis testing, and highlights some of the controversy that has developed around the application of this method. Additionally, we make the argument that studies which will be reported in terms of confidence intervals should similarly be planned with reference to confidence intervals. The sample size should be set to ensure that the estimates of effect size will be reported not only with adequate power but also with appropriate precision.

Mesh:

Year:  1994        PMID: 8001360     DOI: 10.1016/0197-2456(94)90036-1

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  10 in total

Review 1.  Biological interpretation of relative risk.

Authors:  S F Lanes
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

2.  [Statistically significant--also relevant for the patient?].

Authors:  S Lange
Journal:  Med Klin (Munich)       Date:  1999-04-15

3.  Reporting of numerical and statistical differences in abstracts: improving but not optimal.

Authors:  Eric Dryver; Janet E Hux
Journal:  J Gen Intern Med       Date:  2002-03       Impact factor: 5.128

Review 4.  Critical appraisal of scientific articles: part 1 of a series on evaluation of scientific publications.

Authors:  Jean-Baptist du Prel; Bernd Röhrig; Maria Blettner
Journal:  Dtsch Arztebl Int       Date:  2009-02-13       Impact factor: 5.594

5.  Beyond statistical significance: clinical interpretation of rehabilitation research literature.

Authors:  Phil Page
Journal:  Int J Sports Phys Ther       Date:  2014-10

6.  Text message reminders increased colorectal cancer screening in a randomized trial with Alaska Native and American Indian people.

Authors:  Clemma J Muller; Renee F Robinson; Julia J Smith; Meghan A Jernigan; Vanessa Hiratsuka; Denise A Dillard; Dedra Buchwald
Journal:  Cancer       Date:  2016-12-21       Impact factor: 6.860

7.  Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results.

Authors:  A Kavanaugh; S Rosengren; S J Lee; D Hammaker; G S Firestein; K Kalunian; N Wei; D L Boyle
Journal:  Ann Rheum Dis       Date:  2007-07-20       Impact factor: 19.103

8.  Incidence of bone metastasis in carcinoma buccal mucosa.

Authors:  Virendra Bhandari
Journal:  Indian J Med Paediatr Oncol       Date:  2016 Apr-Jun

9.  Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab.

Authors:  Sanna Rosengren; Nathan Wei; Kenneth C Kalunian; Nathan J Zvaifler; Arthur Kavanaugh; David L Boyle
Journal:  Arthritis Res Ther       Date:  2008-09-01       Impact factor: 5.156

10.  Muscle deterioration due to rheumatoid arthritis: assessment by quantitative MRI and strength testing.

Authors:  Matthew Farrow; John Biglands; Steven Tanner; Elizabeth M A Hensor; Maya H Buch; Paul Emery; Ai Lyn Tan
Journal:  Rheumatology (Oxford)       Date:  2021-03-02       Impact factor: 7.580

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.